Development and external validation of a nomogram to predict the prognosis of patients with metastatic prostate cancer who underwent radiotherapy.

ABSTRACT:

Background

Metastatic prostate cancer (mPCa) complicates treatment due to its unpredictable progression. Current prognostic tools often lack precision. This study aimed to develop an effective tool to predict overall survival (OS) in mPCa patients undergoing radiotherapy, thereby addressing the clinical need for personalized treatment decisions.

Methods

A total of 1,171 mPCa patients receiving radiotherapy between 2004 and 2015 were selected from the Surveillance, Epidemiology, and End Results (SEER) database. Patients with distant metastases and complete data on prostate-specific antigen (PSA), Gleason score (GS), and tumor-node-metastasis (TNM) staging were included. The cohort was randomly divided into a training set (n=819) and an internal validation set (n=352). Indepen

SUBMITTER: Zheng F 

PROVIDER: S-EPMC11635567 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature